Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from PreveCeutical Medical ( (TSE:PREV) ).
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has announced its participation in the 43rd JP Morgan Healthcare Conference, aiming to showcase its work in metabolic health and gene-based treatments. The participation of BioGene’s leadership team at this prestigious event underscores the company’s commitment to advancing its position in the life sciences industry and highlights its ongoing research efforts, particularly in addressing diabetes and obesity through innovative therapies.
More about PreveCeutical Medical
PreveCeutical Medical Inc. is a health sciences company dedicated to developing innovative preventive and curative therapies using organic and nature-identical products. The company is involved in various research and development programs focused on dual gene therapy for diabetes and obesity, Nature Identical™ peptides for treating ailments, non-addictive analgesic peptides, and therapies for athletes with concussions. BioGene Therapeutics Inc., a subsidiary, is a Texas-based life sciences company working on metabolic health and gene-based treatments, leveraging Australia’s R&D tax incentives for their research.
YTD Price Performance: 5.56%
Average Trading Volume: 57,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.45M
Find detailed analytics on PREV stock on TipRanks’ Stock Analysis page.
